Ligand Acquires Rights to More Than 15 Development Programs from Selexis SA

By: via Benzinga
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) has acquired a portfolio of potential future milestone and royalty payments for more ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.